A 52-year-old Milwaukee-area man has been accused of faking heart attacks to avoid paying restaurant bills
A 52-year-old Milwaukee-area man has been accused of faking heart attacks to avoid paying restaurant bills and cab fares.
Diabetes drugs would be subject to more stringent safety standards that could cost manufacturers millions of dollars, under recommendations made Wednesday by a government panel.
Most patients see a cardiologist for the first time after a referral from an internist or general practitioner.
Pfizer Inc. and India's Ranbaxy Laboratories Ltd. said Wednesday they have settled their patent dispute over the blockbuster cholesterol drug Lipitor, delaying the release of generic versions in the U.S. until Nov. 30, 2011.
Tim Russert's personal physician says medics tried to save the NBC anchor shortly after he collapsed at work.
Despite passing a stress test on April 29, the newsman's personal doctor says he died of a heart attack
Aggressively treating diabetes does not prevent heart problems and deaths any better than standard treatment for lowering blood sugar, Australian researchers reported recently.
Merck & Co. has halted a study of an experimental drug it had touted as key to energizing its sagging cholesterol franchise, barely three weeks after U.S. regulators refused to allow sales of the drug
Blood cholesterol is a risk factor for coronary artery disease and heart attack, so reducing your risk of high cholesterol is a worthy goal.
A 52-year-old Milwaukee-area man has been accused of faking heart attacks to avoid paying restaurant bills
A 52-year-old Milwaukee-area man has been accused of faking heart attacks to avoid paying restaurant bills and cab fares.
Diabetes drugs would be subject to more stringent safety standards that could cost manufacturers millions of dollars, under recommendations made Wednesday by a government panel.
Most patients see a cardiologist for the first time after a referral from an internist or general practitioner.
Pfizer Inc. and India's Ranbaxy Laboratories Ltd. said Wednesday they have settled their patent dispute over the blockbuster cholesterol drug Lipitor, delaying the release of generic versions in the U.S. until Nov. 30, 2011.
Tim Russert's personal physician says medics tried to save the NBC anchor shortly after he collapsed at work.
Despite passing a stress test on April 29, the newsman's personal doctor says he died of a heart attack
Aggressively treating diabetes does not prevent heart problems and deaths any better than standard treatment for lowering blood sugar, Australian researchers reported recently.
Merck & Co. has halted a study of an experimental drug it had touted as key to energizing its sagging cholesterol franchise, barely three weeks after U.S. regulators refused to allow sales of the drug
Blood cholesterol is a risk factor for coronary artery disease and heart attack, so reducing your risk of high cholesterol is a worthy goal.
A government researcher said Monday that experimental blood substitutes are linked to an increased risk of heart attack and death, and suggested that studies on people should be halted.
Children should be screened for heart problems with an electrocardiogram before getting drugs like Ritalin to treat hyperactivity and attention-deficit disorder, the American Heart Association recommends
Merck said Monday its first-quarter earnings jumped due to income from a partnership, but the drugmaker's sales showed just a slight gain.
A large study offers the strongest evidence yet that a diet the government recommends for lowering blood pressure can save people from heart attack and stroke
Schering-Plough's stock jumped Thursday, after the drugmaker's chief executive announced he would cut 10% of its staff.
Joshua Miller trotted off the football field after making a special-teams play and headed to the bench.
Creating a replacement heart for some of the sickest patients may be one step closer, if new research in rats pans out in humans.
Brian Connell felt the first pains of a heart attack while shoveling snow a year ago. But he was only 38, so he shrugged it off.
Whether it's a partner's snore or an airplane's roar, noises can affect you even if they fail to rouse you from sleep. A new study tries to figure out why
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
Lets face it: All the information around cholesterol makes it something of a confusing topic. Not only do we make our own cholesterol, but we also must have it to produce other important body assets, such as cell membranes and certain types of hormones.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
Merck & Co. reported a surge in fourth-quarter operating earnings Wednesday that exceeded analysts' estimates, but shares slumped in early trading.
More big drugmakers are on tap this week to report strong 2007 earnings, but that's because 2006 was an easy act to follow.
Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.
How's your cholesterol? Here's a guess: If you're healthy, you probably have no idea. New surveys show women tend to be clueless about their risks of heart disease, especially when it comes to managing their cholesterol.
Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.
Surprising study results show that the popular heart drug doesn't live up to its claims -- and three new trials are now under way
Anger, depression and stress can all raise the risk of heart disease -- but a new study shows that chronic anxiety may be even more harmful
The drugmakers Merck and Lilly are the biggest players in Big Pharma's late-stage pipeline, with three possible new blockbusters expected in the coming months.
Jeopardy host Alex Trebek was hospitalized Tuesday after suffering a minor heart attack.
The drugmaker Merck & Co. said Tuesday that it will seek federal approval for two new experimental drugs next year, adding that it's on track to meet its sales targets.
It's been a long time since 66-year-old Judy Borgula has seen the inside of a classroom, but a near-death experience forced her back to school -- "Heart School."
Merck & Co. announced Friday that it will pay $4.85 billion to settle as claims by as many as 47,000 groups of plaintiffs over injuries linked to its blockbuster Vioxx painkiller.
The cause of implantable heart defibrillators took a hit Tuesday when researchers reported the results of two studies that failed to reach their objectives.
A researcher unveiled on Monday the results of a failed Pfizer Inc. study showing that an experimental but dangerous cholesterol drug offers medical benefits too significant to be ignored.
Eli Lilly revealed positive findings from a late-stage trial of its experimental heart drug prasugrel, but a side effect might prevent it from becoming the potential blockbuster that the company had hoped.
Abbott Laboratories unveiled significant test results Sunday for an experimental cholesterol treatment that could go on sale as soon as next year.
Diabetes is the fifth-leading killer of Americans, according to the American Diabetes Association. A sobering two out of three people with type I or type II diabetes will die from a heart attack or stroke -- the combined leading causes of death among diabetics.
New research shows the adage "what doesn't kill us makes us stronger" doesn't apply in treating breast cancer.
Cholesterol-lowering statins may help stave off lung deterioration in the elderly, and even in patients with emphysema and COPD
Studies show that chronic stress contributes to heart attacks and other disease, and researchers think it's time to make stress reduction a medical priority
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.
David Beckham flew back to the U.K. Thursday after his father, Ted Beckham, suffered a heart attack.
Actos and Avandia have entered the spotlight again, as studies published in a leading medical journal pit the two diabetes drugs against each other by comparing their cardiovascular risks.
Patients who switched from the cholesterol-cutting drug Lipitor to the competitor simvastatin increased their risk of suffering heart attacks and strokes, according to a study that Pfizer unveiled on Wednesday.
Patients who switched from the cholesterol-cutting drug Lipitor to the competitor simvastatin increased their risk of suffering heart attacks and strokes, according to a study that Pfizer unveiled on Wednesday.
A new study suggests that popular cholesterol-lowering drugs like Lipitor may help not just the heart, but the brain as well
Deer hunting could be a dangerous endeavor for men with heart disease or risk factors for it, research findings suggest.
Pfizer lost the latest round in a patent battle over the declining blockbuster Lipitor that could be worth $6 billion to the pharma giant.
U.S. regulators said Thursday they are reviewing new safety data on AstraZeneca Plc's heartburn drugs Nexium and Prilosec, but a preliminary analysis does not suggest they increase the risk of heart problems.
Food and Drug Administration panelists voted Monday that GlaxoSmithKline's diabetes drug Avandia should remain on the market, despite an analysis showing links to increased risk of heart attack.
GlaxoSmithKline Plc's widely used diabetes drug Avandia should be pulled off the market, Food and Drug Administration reviewer David Graham said in a presentation prepared for delivery Monday.
People who drank more than one diet soda each day developed the same risks for heart disease as those who downed sugary regular soda
Creating custom food plans for patients isn't the hard part of Bethany Thayer's job. For the Michigan-based registered dietitian and spokesperson for the American Dietetic Association, one of the most difficult aspects of her work is helping patients interpret the often-contradictory health news they hear each day.
Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
GlaxoSmithKline is getting ready for a face-to-face with the FDA about its diabetes drug Avandia, which has been on the hot seat since a study blamed the drug for increasing the risk of heart attack.
Pfizer Inc. on Wednesday reported lower-than-expected quarterly earnings on competition with generics, and said global sales of cholesterol fighter Lipitor fell 13 percent amid slipping demand for the company's flagship product.
Pfizer is not in the best of shape. The beating its stock took on Wednesday shows it. The question is, should the drug maker diet or bulk up?
While being fat increases your chances of a heart attack, some studies suggest a puzzling paradox: Obese people seem have a better chance of surviving one
Debate over the heart attack risk associated with the GlaxoSmithKline diabetes drug Avandia took center stage Monday at the annual meeting of the American Diabetes Association.
Cholesterol-lowering statins - which include the world's top-selling drug, Lipitor - and other drugs called fibrates can lower the risk of developing a common form of nerve damage in diabetics that often results in amputations, according to study results unveiled Friday.
With concerns raised about heart risks of a popular diabetes drug, GlaxoSmithKline and the FDA scramble to respond
The recently published study results that link GlaxoSmithKline's blockbuster diabetes drug Avandia to heart attacks could shift market share to rivals Merck, Lilly and Amylin, despite questions surrounding the data, analysts say.
It's hard out there for drug sales reps--particularly if they work in places where gaining access to doctors is becoming increasingly difficult.
Novartis pulled its irritable bowel syndrome drug Zelnorm off the U.S. market at the FDA's request because of a possible stroke risk to patients, the company said Friday.
An extremely potent experimental cholesterol drug being developed by Eli Lilly and Co. failed to show an advantage over an existing treatment sold by Abbott Laboratories Inc. in a clinical trial that could determine the fate of the medicine.
As Big Pharma faces patent expirations on some of its most lucrative drugs, the industry is trying to reinvigorate sales by finding creative ways to land new patents - but on the same old drugs.
An experimental drug from AtheroGenics and its partner AstraZeneca failed a late-stage clinical trial and is not considered an effective treatment in reducing heart disease, the companies said.
There's nothing unusual about a Big Pharma company with outgoing blockbusters and a weak pipeline. Virtually every major drugmaker in America is struggling with this issue.
The American Heart Association estimates nearly 5 million Americans are living with heart failure. More than half-a-million new cases are diagnosed each year. One of the most common forms is called congestive heart failure. CNN medical correspondent Judy Fortin learned more about it from cardiologist Dr. Wendy Book of Emory School of Medicine.
Heart problems? Me?
When Jean Horgan complained of heart palpitations, her doctor told her it was just nerves.
Novartis could be the hottest drug giant in 2007, analysts say, with Schering-Plough and Eli Lilly & Co. not far behind.
After a rough couple of years dealing with patent expirations and the often frustrating hunt for new products, drug industry executives would love nothing better than an oracle to predict what products in their labs will become the big blockbuster drugs over the next few years.
An FDA advisory committee will be taking a hard look this week at drug-coated stents, which the agency approved back in 2003 to prevent the arteries from re-closing better than non-drug stents.
You'd think 12,000 scientists could fill a drug pipeline. And they probably can. But can they fill it to Wall Street's satisfaction?
Unexpected controversy at the American Heart Association conference over test results of a failed experimental drug pits an independent researcher against a massive drug company and its biotech partner.
Merck & Co. said Monday that its arthritis painkiller Arcoxia does not increase the risk of heart attacks, in a study underscoring the difference between this drug and its withdrawn-from-the-market blockbuster Vioxx.
The California-based biotech Isis Pharmaceuticals could have an effective cholesterol-cutting blockbuster in the works, though it's still early to know for sure.
Merck is experimenting with a new arthritis painkiller that could replace Vioxx, the former billion-dollar blockbuster that has proven to be a liability for the company.
Novartis plans to bring a new arthritis painkiller to the U.S. market, but analysts say its similarity to the disgraced drug Vioxx could kill its chances of becoming a billion-dollar blockbuster.
Even if you're in perfect health now, just thinking about the cost of medical care is bound to make you feel a little ill. With the price of everything from hospital visits to prescription drugs up...
It may be America's No. 1 killer, but people aren't scared enough of heart disease, says a top U.S. research cardiologist.
Federal regulators have approved the first totally implanted artificial heart for patients who aren't eligible for a heart transplant, the Food and Drug Administration announced Tuesday.
Doctors call it "the white-coat effect:" the natural rise in blood pressure that comes with exam-room anxiety. But a simple case of nerves couldn't explain the numbers that Roger Moeller, a 60-year-old editor and publisher in Bethlehem, Connecticut, was hearing during an annual physical.
Merck was found negligent in the latest Vioxx case, as a jury in New Orleans federal court found that the drugmaker misrepresented the risks of the arthritis painkiller and awarded the plaintiff more than $50 million in damages.
This is a good year for Teva Pharmaceuticals. The world's biggest maker of generic drugs is launching nonbranded versions of three major blockbusters: Zocor, Zoloft and Pravachol.
Drugmaker Schering-Plough may have wowed investors with strong second-quarter earnings - but the company has a cholesterol problem.
Merck holds the lead in the ongoing legal war against Vioxx plaintiffs, with five wins and three losses, and experts say it's cheaper for the company to keep paying defense lawyers than to buy off plaintiffs in a mass settlement.
A bowl of broth - that was lunch the day I arrived in Richmond. For dinner, two bottles of lemon-flavored Fleet Phospho-soda and four bisacodyl tablets. You see where this is heading?
Pfizer's old reliable - the anti-cholesterol drug Lipitor - could very well be the hero of the second quarter.
The world's biggest drugmaker is launching a potential blockbuster today, but it's going to take more than that for the company to pull out of its rut.
Merck was found not liable in the seventh lawsuit over Vioxx, the arthritis painkiller that it pulled from the market because of heart attack risk, the company announced Thursday.
The latest lawsuit against Merck over its market-pulled painkiller Vioxx debuts this week in a California courtroom, while the drug giant continues to defend itself in a separate trial in New Jersey.
Two of the biggest blockbuster drugs from the two biggest drugmakers in America are losing patent protection this month, setting the stage for a multi-billion dollar sales vacuum.
A bowl of broth--that was lunch the day I arrived in Richmond. For dinner, two bottles of lemon-flavored Fleet Phospho-soda and four bisacodyl tablets. You see where this is heading? I went to bed ...
Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.
Two of the biggest blockbuster drugs from the two biggest drug makers in America are losing patent protection this month, setting the stage for a multi-billion dollar sales vacuum.
| Most Viewed | Most Emailed | Top Searches |
| Most Viewed | Most Emailed | Top Searches |
Video
